DOCUMENT

RESEARCH NEWS Importantly, neither treatment changed measures of stress or anxiety. This was reassuring, as these behaviours can be affected in DMD and with steroid use. However, we did see clear differences in side effects. Daily prednisolone reduced the size of the adrenal glands. These glands are essential for producing hormones that help the body respond to stress. Weekly vamorolone preserved adrenal gland structure. Overall, our results show that there is no single “perfect” treatment. Instead, there are trade offs. Some approaches may improve muscle strength, while others may reduce muscle damage or cause fewer side effects. This highlights the importance of looking beyond just one outcome. To fully understand treatments for DMD, we need to consider the whole body. This includes muscles, the brain, and hormone systems. Our study also suggests that newer drugs like vamorolone, and alternative dosing schedules, may offer benefits. These approaches could improve quality of life by balancing effectiveness with fewer side effects. In the future, this type of research may help guide more personalised treatment strategies for people living with DMD. Read the full study here: doi.org/10.1113/JP291378 For enquires, contact: Dr Gretel Major gretel.major@canterbury.ac.nz This highlights the importance of looking beyond just one outcome. To fully understand treatments for DMD, we need to consider the whole body. Gretel Major, PhD Postdoctoral Research Fellow Neurology of Myopathies (NoM) Lab University of Canterbury, NZ It is important our members stay well, particularly through the winter months. It is recommended that individuals with neuromuscular conditions receive vaccination for prevention of pneumococcal diseases, such as pneumonia, due to increased risk of not only becoming unwell but also the increased risk of complications if there is an inability to cough and clear the airways effectively. Pneumococcal vaccines are fully funded for children under 5 however government funding is not generally available for older children and adults. For this reason, you may not be eligible to receive a funded vaccine through your local general practice (GP). Because cost is a barrier to having the vaccine, MDANZ has a reimbursement programme available to members who have a neuromuscular condition. MDANZ will reimburse you the cost of receiving the Pneuomvax 23 vaccine at your local GP. Simply go online to complete the reimbursement form with your details, attach your receipt and you will be reimbursed within five working days. www.mda.org.nz/What-We-Offer/ Pneumonia-Vaccine-Funding Pneumonia Vaccine Funding